By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Momenta Pharmaceuticals, Inc. 

675 West Kendall Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-491-9700 Fax: 617-621-0431


SEARCH JOBS
Momenta was founded in 2001 based on technology developed at The Massachusetts Institute of Technology (MIT) for the precise sequencing of complex sugar molecules. This original technology platform and the resulting improvements have driven the company from a small, development-stage start-up to a public company with a leadership position in the analysis and design of complex products. Momenta currently employs a strategy unlike any other company in the biotechnology sector. By utilizing its technology platform to target three separate markets (complex generics, follow-on biologics, and novel drugs) the company spreads its risk while setting the stage for success in multiple product areas.

Momenta’s approach to drug development, linking structure with function,has yielded a diversified product pipeline consisting of both generic and novel complex mixture drugs.We are applying our technology to cellular polysaccharides suchasheparan-sulfate proteoglycans,or HSPGs, polypeptides and proteins. In July 2010, Momenta announced FDA approval for acomplex mixture drug, enoxaparin sodium injection, a generic version of Lovenox®,partnered with Sandoz and developed using our ground-breaking scientific expertise. The current pipeline also includes a generic version of Copaxone®, currently under FDA review, as well as two novel agents and an emerging portfolio of follow-on biologics.

Momenta currently employs 190 people and is headquarterd in Cambridge, MA.


Key Statistics


Email: info@momentapharma.com
Ownership: Public

Web Site: Momenta Pharmaceuticals, Inc.
Employees: 190
Symbol: MNTA
 



Industry
Biotechnology






Company News
Momenta Pharmaceuticals, Inc. (MNTA) Announces Date Of Second Quarter 2014 Financial Results Conference Call And Webcast 7/16/2014 5:48:07 AM
Momenta Pharmaceuticals, Inc. (MNTA) To Webcast Presentation At The Wells Fargo Healthcare Conference 6/10/2014 9:26:56 AM
Momenta Pharmaceuticals, Inc. (MNTA) Receives Orphan Drug Designation For Necuparanib (Formerly M402) In Pancreatic Cancer 6/5/2014 9:24:04 AM
Momenta Pharmaceuticals, Inc. (MNTA) Reports First Quarter 2014 Financial Results 5/6/2014 9:18:31 AM
Momenta Pharmaceuticals, Inc. (MNTA) Announces Presentation Of Data Supporting Sialylation Platform 5/2/2014 9:29:00 AM
Momenta Pharmaceuticals, Inc. (MNTA) To Webcast Presentation At Three Upcoming Investor Conferences 4/30/2014 5:04:25 PM
Momenta Pharmaceuticals, Inc. (MNTA) Announces Date Of First Quarter 2014 Financial Results Conference Call And Webcast 4/16/2014 9:31:17 AM
Momenta Pharmaceuticals, Inc. (MNTA) To Webcast Presentation At The Cowen And Company 34th Annual Health Care Conference 2/25/2014 8:55:29 AM
Momenta Pharmaceuticals, Inc. (MNTA) Reports Fourth Quarter And Year End 2013 Financial Results 2/10/2014 9:15:17 AM
Momenta Pharmaceuticals, Inc. (MNTA) To Webcast Presentation At The 2014 Leerink Swann and Company Global Healthcare Conference 2/5/2014 9:11:12 AM
12345678910...
//-->